Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003849 · ClinicalTrials.gov registry record · Phase 2

Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

A Phase 2 study of Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 2
Development phase
39
Enrollment target
20
Study locations

NCT00003849 is a Phase 2 study of Lymphoma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 39 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003849, a Phase 2 study of Lymphoma, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
39 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them. PURPOSE: Phase II trial to study the effectiveness of rituximab in treating patients who have non-Hodgkin's lymphoma or Hodgkin's disease.

Conditions Studied

Lymphoma

Interventions

  • BIOLOGICAL rituximab

Study Locations (20)

Minnesota

  • CCOP - Duluth - Duluth
  • Mayo Clinic Cancer Center - Rochester
  • CentraCare Clinic - Saint Cloud
  • CCOP - Metro-Minnesota - Saint Louis Park

Iowa

  • CCOP - Cedar Rapids Oncology Project - Cedar Rapids
  • CCOP - Iowa Oncology Research Association - Des Moines
  • Siouxland Hematology-Oncology - Sioux City

North Dakota

  • Quain & Ramstad Clinic, P.C. - Bismarck
  • CCOP - Merit Care Hospital - Fargo
  • Altru Health Systems - Grand Forks

Illinois

  • CCOP - Illinois Oncology Research Association - Peoria
  • CCOP - Carle Cancer Center - Urbana

South Dakota

  • Rapid City Regional Hospital - Rapid City
  • CCOP - Sioux Community Cancer Consortium - Sioux Falls

Arizona

  • CCOP - Scottsdale Oncology Program - Scottsdale

Kansas

  • CCOP - Wichita - Wichita

Louisiana

  • CCOP - Ochsner - New Orleans

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 1999-07
Est. Completion 2008-02
Phase Phase 2

Sponsor

Alliance for Clinical Trials in Oncology

446 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00003849

The ClinicalTrials.gov registry entry for NCT00003849 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which rituximab is the first listed.

NCT00003849 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Minnesota, Iowa, North Dakota.

Frequently Asked Questions

What is clinical trial NCT00003849 about?

NCT00003849 is a clinical study titled "Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease". RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them. PURPOSE: Phase II trial to study the effectiveness of rituximab in treating patients who have non-Hodgkin's lymphoma or Hodgkin's disease.

What is the current status of trial NCT00003849?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 1999-07. Estimated completion is 2008-02.

What conditions does trial NCT00003849 study?

This clinical trial studies the following conditions: Lymphoma.

What interventions are being tested in trial NCT00003849?

The interventions under investigation include: rituximab (BIOLOGICAL).

Who is sponsoring clinical trial NCT00003849?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003849 being conducted?

This trial has 20 study locations across Arizona, Illinois, Iowa, Kansas, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.